Real World Evidence Market: Market Segments: By Component (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data and Others); By End User (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies and Others); By Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease and Others) and Region – Global Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2030
Product Overview
Real-world data is derived from various sources associated with the outcomes of the heterogeneous population of patients in real-world settings. It is the clinical confirmation regarding the consumption and potential risks or benefits of a medical product. Real-world data sets are extensively used for various applications such as market access & reimbursement/ coverage decisions, drug development & approvals, medical device development & approvals and clinical decision-making for real-world evidence which aids in the growth of the overall market.Market Highlights
Global Real World Evidence Market is expected to project a notable CAGR of 15.95% in 2030.
Global Real World Evidence Market to surpass USD 4.74 billion by 2030 from USD 1.11 billion in 2020 at a CAGR of 15.95% in the coming years, i.e., 2020-30. RWE market is growing due to rising geriatric population, a shift in value to the volume-based, mounting prevalence of chronic diseases, delays in drug development, and the subsequent increase in development costs which can be improved with the usage of real-world data sets that work as clinical evidence and recognized as efficient solutions by various pharmaceutical companiesGlobal Real World Evidence Market: Segments
Oncology segment to grow with the highest CAGR during 2020-30
Global Real World Evidence Market is segmented by therapeutic area into Oncology, Immunology, Neurology, Cardiovascular Disease, and Others. The oncology segment held the largest market share of XX.X% in the year 2019 owing to the rising prevalence of cancer across the globe and the conduct of a significant number of clinical oncology trials.Market Dynamics
Drivers
Delayed drug development and high development costs
Development of a new pharmaceutical drug is of high risk with fewer chances for a successful outcome, time-consuming, and extremely costly. Healthcare and research organizations confront challenges posed by high costs and lengthy timelines to deliver medicines due to the hike in the emergence of rare diseases and growing inclination towards personalized healthcare. Many companies seek possible ways to cut down the cost of clinical trials and evade barriers to escalate the drug development process.Restraint
Stringent government regulations
Strict government regulations and policies impede the growth of the global market since the manufacturers are required to obtain permits, licenses, product registrations, and other regulatory approvals to fulfill the security and operating standards of various government bodies. Also, the lack of a universally accepted standard for data collection and reluctance to depend upon real-world studies is expected to limit the growth of the global market.
Global Real World Evidence Market: Key Players
IQVIA
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
IBM Corporation
Cognizant
Oracle Corporation
Syneos Health
Pharmaceutical Product Development
Clinigen Group plc
PAREXEL International Corporation
Palantir Technologies
SAS
Other Prominent Players
Global Real World Evidence Market: Regions
Global Real World Evidence Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Global Real World Evidence Market in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Real World Evidence Market due to the presence of a well-established pharmaceutical industry, favorable regulatory environment, persistent expenditure in research & development activities which is projected to boost the market in this region.
Real-world data is derived from various sources associated with the outcomes of the heterogeneous population of patients in real-world settings. It is the clinical confirmation regarding the consumption and potential risks or benefits of a medical product. Real-world data sets are extensively used for various applications such as market access & reimbursement/ coverage decisions, drug development & approvals, medical device development & approvals and clinical decision-making for real-world evidence which aids in the growth of the overall market.Market Highlights
Global Real World Evidence Market is expected to project a notable CAGR of 15.95% in 2030.
Global Real World Evidence Market to surpass USD 4.74 billion by 2030 from USD 1.11 billion in 2020 at a CAGR of 15.95% in the coming years, i.e., 2020-30. RWE market is growing due to rising geriatric population, a shift in value to the volume-based, mounting prevalence of chronic diseases, delays in drug development, and the subsequent increase in development costs which can be improved with the usage of real-world data sets that work as clinical evidence and recognized as efficient solutions by various pharmaceutical companiesGlobal Real World Evidence Market: Segments
Oncology segment to grow with the highest CAGR during 2020-30
Global Real World Evidence Market is segmented by therapeutic area into Oncology, Immunology, Neurology, Cardiovascular Disease, and Others. The oncology segment held the largest market share of XX.X% in the year 2019 owing to the rising prevalence of cancer across the globe and the conduct of a significant number of clinical oncology trials.Market Dynamics
Drivers
Delayed drug development and high development costs
Development of a new pharmaceutical drug is of high risk with fewer chances for a successful outcome, time-consuming, and extremely costly. Healthcare and research organizations confront challenges posed by high costs and lengthy timelines to deliver medicines due to the hike in the emergence of rare diseases and growing inclination towards personalized healthcare. Many companies seek possible ways to cut down the cost of clinical trials and evade barriers to escalate the drug development process.Restraint
Stringent government regulations
Strict government regulations and policies impede the growth of the global market since the manufacturers are required to obtain permits, licenses, product registrations, and other regulatory approvals to fulfill the security and operating standards of various government bodies. Also, the lack of a universally accepted standard for data collection and reluctance to depend upon real-world studies is expected to limit the growth of the global market.
Global Real World Evidence Market: Key Players
IQVIA
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
IBM Corporation
Cognizant
Oracle Corporation
Syneos Health
Pharmaceutical Product Development
Clinigen Group plc
PAREXEL International Corporation
Palantir Technologies
SAS
Other Prominent Players
Global Real World Evidence Market: Regions
Global Real World Evidence Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Global Real World Evidence Market in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Real World Evidence Market due to the presence of a well-established pharmaceutical industry, favorable regulatory environment, persistent expenditure in research & development activities which is projected to boost the market in this region.
1. CONTENTS
2. EXECUTIVE SUMMARY
3. GLOBAL REAL WORLD EVIDENCE MARKET
3.1. Product Overview
3.2. Market Definition
3.3. Segmentation
3.4. Assumptions and Acronyms
4. RESEARCH METHODOLOGY
4.1. Research Objectives
4.2. Primary Research
4.3. Secondary Research
4.4. Forecast Model
4.5. Market Size Estimation
5. AVERAGE PRICING ANALYSIS
6. MACRO-ECONOMIC INDICATORS
7. MARKET DYNAMICS
7.1. Growth Drivers
7.2. Restraints
7.3. Opportunity
7.4. Trends
8. CORRELATION & REGRESSION ANALYSIS
8.1. Correlation Matrix
8.2. Regression Matrix
9. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
10. RISK ANALYSIS
10.1. Demand Risk Analysis
10.2. Supply Risk Analysis
11. GLOBAL REAL WORLD EVIDENCE ANALYSIS
11.1. Porters Five Forces
11.1.1. Threat of New Entrants
11.1.2. Bargaining Power of Suppliers
11.1.3. Threat of Substitutes
11.1.4. Rivalry
11.2. PEST Analysis
11.2.1. Political
11.2.2. Economic
11.2.3. Social
11.2.4. Technological
12. GLOBAL REAL WORLD EVIDENCE MARKET
12.1. Market Size & forecast, 2020A-2030F
12.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. GLOBAL REAL-WORLD EVIDENCE: MARKET SEGMENTATION
13.1. By Regions
13.1.1. North America:(U.S. and Canada) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2. By Component: Market Share (2020-2030F)
13.2.1. Claims Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.2. Clinical Settings Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.3. Patient-Powered Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.4. Pharmacy Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3. By End-User: Market Share (2020-2030F)
13.3.1. Healthcare Providers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2020-2030
13.3.2. Pharmaceutical & Medical Device Companies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3.3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4. By Therapeutic Area: Market Share (2020-2030F)
13.4.1. Oncology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.2. Immunology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.3. Neurology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.4. Cardiovascular Disease, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.5. Other Solutions, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14. COMPANY PROFILE
15. IQVIA
15.1. Company Overview
15.2. Company Total Revenue (Financials)
15.3. Market Potential
15.4. Global Presence
15.5. Key Performance Indicators
15.6. SWOT Analysis
15.7. Product Launch
16. IBM CORPORATION
17. COGNIZANT
18. ORACLE CORPORATION
19. SYNEOS HEALTH
20. PHARMACEUTICAL PRODUCT DEVELOPMENT
21. CLINIGEN GROUP PLC
22. PAREXEL INTERNATIONAL CORPORATION
23. PALANTIR TECHNOLOGIES
24. SAS
25. OTHER PROMINENT PLAYERS
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. EXECUTIVE SUMMARY
3. GLOBAL REAL WORLD EVIDENCE MARKET
3.1. Product Overview
3.2. Market Definition
3.3. Segmentation
3.4. Assumptions and Acronyms
4. RESEARCH METHODOLOGY
4.1. Research Objectives
4.2. Primary Research
4.3. Secondary Research
4.4. Forecast Model
4.5. Market Size Estimation
5. AVERAGE PRICING ANALYSIS
6. MACRO-ECONOMIC INDICATORS
7. MARKET DYNAMICS
7.1. Growth Drivers
7.2. Restraints
7.3. Opportunity
7.4. Trends
8. CORRELATION & REGRESSION ANALYSIS
8.1. Correlation Matrix
8.2. Regression Matrix
9. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
10. RISK ANALYSIS
10.1. Demand Risk Analysis
10.2. Supply Risk Analysis
11. GLOBAL REAL WORLD EVIDENCE ANALYSIS
11.1. Porters Five Forces
11.1.1. Threat of New Entrants
11.1.2. Bargaining Power of Suppliers
11.1.3. Threat of Substitutes
11.1.4. Rivalry
11.2. PEST Analysis
11.2.1. Political
11.2.2. Economic
11.2.3. Social
11.2.4. Technological
12. GLOBAL REAL WORLD EVIDENCE MARKET
12.1. Market Size & forecast, 2020A-2030F
12.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. GLOBAL REAL-WORLD EVIDENCE: MARKET SEGMENTATION
13.1. By Regions
13.1.1. North America:(U.S. and Canada) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2. By Component: Market Share (2020-2030F)
13.2.1. Claims Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.2. Clinical Settings Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.3. Patient-Powered Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.4. Pharmacy Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3. By End-User: Market Share (2020-2030F)
13.3.1. Healthcare Providers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2020-2030
13.3.2. Pharmaceutical & Medical Device Companies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3.3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4. By Therapeutic Area: Market Share (2020-2030F)
13.4.1. Oncology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.2. Immunology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.3. Neurology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.4. Cardiovascular Disease, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4.5. Other Solutions, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14. COMPANY PROFILE
15. IQVIA
15.1. Company Overview
15.2. Company Total Revenue (Financials)
15.3. Market Potential
15.4. Global Presence
15.5. Key Performance Indicators
15.6. SWOT Analysis
15.7. Product Launch
16. IBM CORPORATION
17. COGNIZANT
18. ORACLE CORPORATION
19. SYNEOS HEALTH
20. PHARMACEUTICAL PRODUCT DEVELOPMENT
21. CLINIGEN GROUP PLC
22. PAREXEL INTERNATIONAL CORPORATION
23. PALANTIR TECHNOLOGIES
24. SAS
25. OTHER PROMINENT PLAYERS
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
